ストックスクリーナーアプリを入手
8.155
3.72%
-0.315
Ocular Therapeutix Inc (OCUL) 最新ニュース
Ocular Therapeutix Inc (OCUL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OCUL|Ocular Therapeutix Inc|Price:8.505|Chg%:-0.115 - TradingKey
Ocular Therapeutix Inc (OCUL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ocular Therapeutix Inc (OCUL) Cash Flow - TradingKey
Ocular Therapeutix Inc (OCUL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ocular Therapeutix Inc (OCUL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ocular Therapeutix Market Sentiment - Benzinga
Ocular Therapeutix Inc Revenue Breakdown – BX:0OT - TradingView
Ocular Therapeutix Inc (OCUL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Is Ocular Therapeutix (OCUL) Still Undervalued Or Is AXPAXLI Hope Already Priced In? - Yahoo Finance
(OCUL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment - Yahoo Finance
Ocular Therapeutix at H.C. Wainwright: FDA path clears for AXPAXLI By Investing.com - Investing.com South Africa
Ocular Therapeutix at H.C. Wainwright: FDA path clears for AXPAXLI - Investing.com
Ocular Therapeutix, Inc. (OCUL) Stock Analysis: Unpacking The 211% Potential Upside - DirectorsTalk Interviews
Citizens reiterates Ocular Therapeutix stock rating on Dextenza sales - Investing.com
Citizens reiterates Ocular Therapeutix stock rating on Dextenza sales By Investing.com - Investing.com Canada
Ocular Therapeutix Inc (OCUL) Institutional Confidence - TradingKey
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Does Ocular Therapeutix (OCUL) Joining Russell Value Indexes Quietly Recast Its Long‑Term Investor Base? - simplywall.st
FDA approves Dextenza for third indication: Ocular itching from allergic conjunctivitis - Ophthalmology Times Europe
Ocular Therapeutix gives 11 new hires stock awards worth 46,075 shares - Stock Titan
Ocular Therapeutix (OCUL) Joins Russell Value Indexes, Is The Stock Now Too Pricey? - Sahm
Ocular Therapeutix (OCUL) Holds Steady Near Key Support Levels Amid Low VolumeOn Balance Volume - dars.gov.et
Ocular Therapeutix options trading jumps to 9,894 contracts By Investing.com - Investing.com Canada
Ocular Therapeutix options trading jumps to 9,894 contracts - Investing.com
Ocular Therapeutix Inc Actuals & Estimates (NASDAQ:OCUL) - TradingView
Price to earnings forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView
Ocular Therapeutix Inc to Host Investor Day Transcript - GuruFocus
Enterprise value to revenue forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView
Price to sales forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView
Price to book forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView
Enterprise value to EBIT forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView
Enterprise value to EBITDA forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView
Ocular Therapeutix to present new retinal disea... - Pluang
Does Broad Russell Value Index Inclusion Reshape the Bull Case for Ocular Therapeutix (OCUL)? - simplywall.st
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences - The Manila Times
Ocular Therapeutix will present SOL-1 data at July retina meetings - Stock Titan
(OCUL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Ocular Therapeutix, Inc.(NasdaqGM: OCUL) added to Russell 2000 Value Benchmark - marketscreener.com
Ocular Therapeutix (OCUL) Could Be 62% Below Fair Value After Axpaxli FDA Feedback - Sahm
Ocular Therapeutix, Inc.(NasdaqGM: OCUL) added to Russell 2500 Value Benchmark - marketscreener.com
Ocular Therapeutix, Inc.(NasdaqGM: OCUL) added to Russell 3000 Value Benchmark - marketscreener.com
OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda? - Stocktwits
OCUL News | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill
OCUL Forecast — Price Target — Prediction for 2027 - TradingView
Ocular Therapeutix Inc Actuals & Estimates (BX:0OT) - TradingView
Ocular Therapeutix Inc Actuals & Estimates (HAM:0OT) - TradingView
Chardan Capital Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $23 - Moomoo
OCUL Maintained by Chardan Capital -- Price Target Raised to $23 - GuruFocus
Is Ocular Therapeuticx, Inc. (OCUL) Stock Positioned for Growth After Positive FDA Feedback on Axpaxli? - Yahoo Finance
5 Best Healthcare Stocks to Buy According to Wall Street Analysts - Insider Monkey
Ocular Therapeutix (OCUL): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
BofA Securities Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $27 - Moomoo
H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $25 - Moomoo
H.C. Wainwright raises Ocular Therapeutix price target to $25 on FDA pathway clarity - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):